Lymphocyte-specific TRAF3 transgenic mice have enhanced humoral responses and develop plasmacytosis, autoimmunity, inflammation, and cancer

Blood

Volumn 113, Issue 19, 2009, Pages 4595-4603

  Zapata, Juan M ^a,b   Llobet, David ^a,c   Krajewska, Maryla ^a   Lefebvre, Sophie ^a,d   Kress, Christina L ^a   Reed, John C ^a  

^a BURNHAM INSTITUTE   (United States)

^b CENTRO DE BIOLOGÍA MOLECULAR SEVERO OCHOA   (Spain)

^c HOSPITAL UNIVERSITARI ARNAU DE VILANOVA   (Spain)

^d NONE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

B CELL ACTIVATING FACTOR RECEPTOR; CARCINOGEN; CD40 ANTIGEN; CYTOKINE; IMMUNOGLOBULIN G; PROTEIN NIK; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 3; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE; CACHEXIA; CANCER RISK; CANCER SUSCEPTIBILITY; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; HEAD AND NECK CANCER; HUMORAL IMMUNITY; HYPERGAMMAGLOBULINEMIA; INFLAMMATION; LIFESPAN; LYMPHOCYTE; LYMPHOID ORGAN; MALE; MOUSE; NEOPLASM; NONHUMAN; PLASMACYTOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SALIVARY GLAND TUMOR; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; TRANSGENIC MOUSE; ANIMAL; BLOOD; ENZYME IMMUNOASSAY; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOBLOTTING; IMMUNOLOGY; PATHOLOGY; PHYSIOLOGY; PLASMA CELL; SIGNAL TRANSDUCTION;

ANIMALS; AUTOIMMUNITY; B-LYMPHOCYTES; CELL PROLIFERATION; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HUMANS; HYPERGAMMAGLOBULINEMIA; IMMUNOBLOTTING; IMMUNOENZYME TECHNIQUES; IMMUNOGLOBULIN G; INFLAMMATION; MALE; MICE; MICE, TRANSGENIC; NEOPLASMS; PLASMA CELLS; SIGNAL TRANSDUCTION; TNF RECEPTOR-ASSOCIATED FACTOR 3; TOLL-LIKE RECEPTORS;

EID: 66549089712     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-07-165456     Document Type: Article

References (30)

1. Zapata JM. TRAF3: B cells and beyond. Mod Asp Immunobiol. 2002;2:236-240.
2. Zapata JM, Martinez-Garcia V, Lefebvre S. Phylogeny of the TRAF/MATH domain. Adv Exp Med Biol. 2007;597:1-24.
3. He JQ, Oganesyan G, Saha SK, Zarnegar B, Cheng G. TRAF3 and its biological function. Adv Exp Med Biol. 2007;597:48-59.
4. Zapata JM, Lefebvre S, Reed JC. Targeting TRAfs for therapeutic intervention. Adv Exp Med Biol. 2007;597:188-201.
5. Hauer J, Puschner S, Ramakrishnan P, et al. TNF receptor (TNFR)-associated factor (TRAF) 3 serves as an inhibitor of TRAF2/5-mediated activation of the noncanonical NF-κB pathway by TRAF-binding TNFRs. Proc Natl Acad Sci U S A. 2005;102:2874-2879. (Pubitemid 40299884)
6. Liao G, Zhang M, Harhaj EW, Sun SC. Regulation of the NF-κB-inducing kinase by tumor necrosis factor receptor-associated factor 3-induced degradation. J Biol Chem. 2004;279:26243-26250. (Pubitemid 38798772)
7. He JQ, Zarnegar B, Oganesyan G, et al. Rescue of TRAF3-null mice by p100 NF-κ B deficiency. J Exp Med. 2006;203:2413-2418. (Pubitemid 44664610)
8. Xie P, Stunz LL, Larison KD, Yang B, Bishop GA. Tumor necrosis factor receptor-associated factor 3 is a critical regulator of B cell homeostasis in secondary lymphoid organs. Immunity. 2007;27:253-267. (Pubitemid 47284931)
9. Keats JJ, Fonseca R, Chesi M, et al. Promiscuous mutations activate the noncanonical NF-κB pathway in multiple myeloma. Cancer Cell. 2007;12:131-144. (Pubitemid 47208626)
10. Annunziata CM, Davis RE, Demchenko Y, et al. Frequent engagement of the classical and alternative NF-κB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell. 2007;12:115-130. (Pubitemid 47199123)
11. Oganesyan G, Saha SK, Guo B, et al. Critical role of TRAF3 in the Toll-like receptor-dependent and -independent antiviral response. Nature. 2005;439:208-211. (Pubitemid 43083142)
12. Hacker H, Redecke V, Blagoev B, et al. Specificity in Toll-like receptor signalling through distinct effector functions of TRAF3 and TRAF6. Nature. 2005;439:204-207. (Pubitemid 43083141)
13. Saha SK, Pietras EM, He JQ, et al. Regulation of antiviral responses by a direct and specific interaction between TRAF3 and cardif. EMBO J. 2006;25:3257-3263.
14. Kayagaki N, Phung Q, Chan S, et al. DUBA: a deubiquitinase that regulates type I interferon production. Science. 2007;318:1628-1632. (Pubitemid 350233662)
15. Pasare C, Medzhitov R. Control of B-cell responses by Toll-like receptors. Nature. 2005;438:364-368. (Pubitemid 41643953)
16. Krajewski S, Zapata JM, Krajewski M, et al. Immunohistochemical analysis of in vivo patterns of TRAF-3 expression, a member of the TNF receptor-associated factor family. J Immunol. 1997;159:5841-5852. (Pubitemid 127471518)
17. Zapata JM, Takahashi R, Salvesen GS, Reed JC. Granzyme release and caspase activation in activated human T-lymphocytes. J Biol Chem. 1998;273:6916-6920. (Pubitemid 28160356)
18. Lee SY, Reichlin A, Santana A, Sokol KA, Nussenzweig MC, Choi Y. TRAF2 is essential for JNK but not NF-κB activation and regulates lymphocyte proliferation and survival. Immunity. 1997;7:703-713. (Pubitemid 28156637)
19. Grech AP, Amesbury M, Chan T, Gardam S, Basten A, Brink R. TRAF2 differentially regulates the canonical and noncanonical pathways of NF-κB activation in mature B cells. Immunity. 2004;21:629-642. (Pubitemid 39487887)
20. Hostager BS, Haxhinasto SA, Rowland SL, Bishop GA. Tumor necrosis factor receptor-associated factor 2 (TRAF2)-deficient B lymphocytes reveal novel roles for TRAF2 in CD40 signaling. J Biol Chem. 2003;278:45382-45390. (Pubitemid 37432675)
21. Shapiro-Shelef M, Calame K. Regulation of plasma-cell development. Nat Rev Immunol. 2005;5:230-242.
22. Nacionales DC, Kelly KM, Lee PY, et al. Type I interferon production by tertiary lymphoid tissue developing in response to 2,6,10,14-tetramethyl- pentadecane (pristane). Am J Pathol. 2006;168:1227-1240.
23. Potter M, Morrison S, Wiener F, Zhang XK, Miller FW. Induction of plasmacytomas with silicone gel in genetically susceptible strains of mice. J Natl Cancer Inst. 1994;86:1058-1065. (Pubitemid 24228472)
24. Krieg AM, Vollmer J. Toll-like receptors 7, 8, and 9: linking innate immunity to autoimmunity. Immunol Rev. 2007;220:251-269.
25. He JQ, Saha SK, Kang JR, Zarnegar B, Cheng G. Specificity of TRAF3 in its negative regulation of the noncanonical NF-κ B pathway. J Biol Chem. 2007;282:3688-3694. (Pubitemid 47084476)
26. Tan TT, Coussens LM. Humoral immunity, inflammation and cancer. Curr Opin Immunol. 2007;19:209-216.
27. Chen K, Huang J, Gong W, Iribarren P, Dunlop NM, Wang JM. Toll-like receptors in inflammation, infection and cancer. Int Immunopharmacol. 2007;7:1271-1285. (Pubitemid 47126372)
28. Carlson JA, Ambros R, Malfetano J, et al. Vulvar lichen sclerosus and squamous cell carcinoma: a cohort, case control, and investigational study with historical perspective; implications for chronic inflammation and sclerosis in the development of neoplasia. Hum Pathol. 1998;29:932-948. (Pubitemid 28422041)
29. Shacter E, Weitzman SA. Chronic inflammation and cancer. Oncology (Williston Park). 2002;16:217-226, 229; discussion 230-1212
30. de Visser KE, Korets LV, Coussens LM. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell. 2005;7:411-423.